MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

CytomX Therapeutics Inc

Fermé

SecteurSoins de santé

2.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.37

Max

2.49

Chiffres clés

By Trading Economics

Revenu

4.6M

24M

Ventes

13M

51M

P/E

Moyenne du Secteur

4.979

39.857

Marge bénéficiaire

46.203

Employés

119

EBITDA

4.9M

23M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+89.08% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

210M

381M

Ouverture précédente

2.38

Clôture précédente

2.38

Sentiment de l'Actualité

By Acuity

61%

39%

319 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

CytomX Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 juil. 2025, 21:01 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 20:46 UTC

Résultats

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 juil. 2025, 20:39 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 20:36 UTC

Résultats

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 juil. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 juil. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 juil. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 juil. 2025, 18:24 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 juil. 2025, 18:19 UTC

Résultats

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 juil. 2025, 18:11 UTC

Acquisitions, Fusions, Rachats

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 juil. 2025, 18:11 UTC

Résultats

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 juil. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 juil. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 juil. 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 16:04 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 juil. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 juil. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 juil. 2025, 15:47 UTC

Market Talk
Résultats

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparaison

Variation de prix

CytomX Therapeutics Inc prévision

Objectif de Prix

By TipRanks

89.08% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  89.08%

Haut 5 USD

Bas 3.5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.7658 / N/ASupport & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

319 / 376Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.